- The company plan to initiate a pivotal P-IIIa program to assess the efficacy and safety of oral semaglutide (50mg) vs PBO in ~1000 people with obesity or overweight with comorbidities for 68wks.
- The initiation follows the completion of the STEP P-IIIa clinical program with semaglutide (2.4mg, qw, SC). The study is expected to initiate the study in H2’21
- Oral semaglutide is a convenient and effective treatment option for people with obesity and HCPs enabling broader use of anti-obesity medication
Click here to read full press release/ article | Ref: Globe Newswire | Image: Mehr News Agency